Management of infection in children with bone marrow failure.
The development of new and often more successful regimens of treatment for childhood blood and malignant diseases has usually been associated with a parallel increase in infectious problems. This is because these successes have often, in the absence of new effective drugs, been achieved by increasing drug dose intensity to new limits. This chapter is not intended to deal with every possible infection, but rather to be a practical guide to the current management of infection. The last few years have seen major improvements in the development of haematopoietic growth factors, new antifungal agents, new antibiotics and new ways to use aminoglycosides. Attempts are being made to identify good and poor risk factors for the outcome of infection in order to facilitate shorter courses and possibly home or day care use of antimicrobial agents. In addition the different needs of children are being recognized in view of the restricted use of quinolones in this group and the different organisms and types of infection that they experience.
Hann
I M
IM
Great Ormond Street Children's Hospital, London, UK.
D000970:Antineoplastic Agents / Q000009:adverse effects*; D001424:Bacterial Infections / Q000188:drug therapy / Q000209:etiology / Q000517:prevention & control; D002648:Child; D016298:Hematopoietic Cell Growth Factors / Q000627:therapeutic use; D006801:Humans; D007239:Infections / Q000188:drug therapy* / Q000209:etiology*; D007938:Leukemia / Q000188:drug therapy*; D009181:Mycoses / Q000188:drug therapy / Q000209:etiology / Q000517:prevention & control; D009503:Neutropenia / Q000150:complications* / Q000209:etiology*; D014777:Virus Diseases / Q000188:drug therapy / Q000209:etiology / Q000517:prevention & control
D000970:Antineoplastic Agents; D016298:Hematopoietic Cell Growth Factors